多西他赛致间质性肺炎在68Ga-PSMA PET/CT上的检出
本文报道一例转移性去势抵抗性前列腺癌患者,在接受多西他赛治疗后,于68Ga-PSMA PET/CT上检出多西他赛诱导的间质性肺炎。文中指出68Ga-PSMA PET/CT常用于生化复发后中高危前列腺癌分期,且良性病变也可出现68Ga-PSMA摄取;多西他赛主要治疗不良反应包括骨髓抑制、脱发和乏力,间质性肺炎见于不足2%的多西他赛治疗患者。
要点
- 68Ga-PSMA PET/CT可用于检出多西他赛诱导的间质性肺炎。
- 多西他赛治疗患者中间质性肺炎发生率不足2%。
- 68Ga-PSMA在良性病变中也可出现摄取,需注意鉴别。
核心结论
- 多西他赛诱导的间质性肺炎可在68Ga-PSMA PET/CT上被检出。
研究设计与样本
- 本文为个案报道,对象为一例转移性去势抵抗性前列腺癌患者。
主要发现
- 该患者在多西他赛治疗后,68Ga-PSMA PET/CT检出多西他赛诱导的间质性肺炎。
关键数值与推荐
- 间质性肺炎见于不足2%的多西他赛治疗患者。
- 多西他赛主要治疗相关不良反应包括骨髓抑制、脱发和乏力。
临床怎么用
- 前列腺癌患者多西他赛治疗后行68Ga-PSMA PET/CT时,应关注间质性肺炎的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-PSMA PET/CT is a commonly performed procedure in the staging of intermediate- and high-risk prostate cancer after biochemical recurrence. Uptake of 68Ga-PSMA in benign conditions is also reported in the literature. Docetaxel is the mainstay of treatment in high-volume hormone-sensitive prostate cancer and castration-resistant prostate cancer. The major treatment-emergent adverse drug reactions attributed to docetaxel include myelosuppression, alopecia, and asthenia. Interstitial pneumonitis is seen in less than 2% of docetaxel-treated patients. We present a case of metastatic castration-resistant prostate cancer, wherein docetaxel-induced interstitial pneumonitis was detected on 68Ga-PSMA PET/CT, after docetaxel treatment.
引用
- Kumar S, Singh H, Das CK, et al. Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT. Clin Nucl Med. 2021. PMID: 33315676. doi:10.1097/RLU.0000000000003445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。